The effect of sorafenib (Nexavar) on 111-indium labeled chimeric monoclonal antibody G250 [WX-G250] or 111-indium labeled bevacizumab (Avastin) uptake in patients with clear cell RCC [renal cell carcinoma] (ccRCC)

Trial Profile

The effect of sorafenib (Nexavar) on 111-indium labeled chimeric monoclonal antibody G250 [WX-G250] or 111-indium labeled bevacizumab (Avastin) uptake in patients with clear cell RCC [renal cell carcinoma] (ccRCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Feb 2012 Planned End Date changed from 1 Dec 2008 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 27 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top